Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Cetuximab + Irinotecan vs Standard-of-Care in 3L RAS Wild-Type mCRC
NCT05278351Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05278351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278351.